478 related articles for article (PubMed ID: 21802835)
1. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.
Bjartell A
Eur Urol; 2011 Nov; 60(5):905-7. PubMed ID: 21871707
[No Abstract] [Full Text] [Related]
3. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
5. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Boissier E; Loriot Y; Vignot S; Massard C
Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
9. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
11. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
13. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
[TBL] [Abstract][Full Text] [Related]
14. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
[TBL] [Abstract][Full Text] [Related]
15. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells.
Mao X; Shaw G; James SY; Purkis P; Kudahetti SC; Tsigani T; Kia S; Young BD; Oliver RT; Berney D; Prowse DM; Lu YJ
Asian J Androl; 2008 May; 10(3):467-73. PubMed ID: 18385909
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR.
Fernández-Serra A; Rubio L; Calatrava A; Rubio-Briones J; Salgado R; Gil-Benso R; Espinet B; García-Casado Z; López-Guerrero JA
Biomed Res Int; 2013; 2013():465179. PubMed ID: 23781502
[TBL] [Abstract][Full Text] [Related]
18. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Lorente D; Olmos D; Mateo J; Bianchini D; Seed G; Fleisher M; Danila DC; Flohr P; Crespo M; Figueiredo I; Miranda S; Baeten K; Molina A; Kheoh T; McCormack R; Terstappen LW; Scher HI; de Bono JS
Eur Urol; 2016 Dec; 70(6):985-992. PubMed ID: 27289566
[TBL] [Abstract][Full Text] [Related]
19. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
20. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]